Show simple item record

dc.contributor.authorGunnarsdottir, Anna Ingibjorg
dc.contributor.authorGudjonsson, Hallgrimur
dc.contributor.authorHardardottir, Hjordis
dc.contributor.authorJonsdottir, Karen Drofn
dc.contributor.authorBjornsson, Einar Stefan
dc.date.accessioned2017-08-23T14:33:41Z
dc.date.available2017-08-23T14:33:41Z
dc.date.issued2017-09
dc.date.submitted2017
dc.identifier.citationAntibiotic susceptibility of Helicobacter pylori in Iceland. 2017, 49 (9):647-654 Infect Dis (Lond)en
dc.identifier.issn2374-4243
dc.identifier.pmid28440099
dc.identifier.doi10.1080/23744235.2017.1317359
dc.identifier.urihttp://hdl.handle.net/2336/620275
dc.descriptionTo access publisher's full text version of this article click on the hyperlink belowen
dc.description.abstractIncreasing resistance of Helicobacter pylori (H. pylori) to antibiotics calls for constant re-evaluation of multidrug regimens that have been used to eradicate the infection. The aim of this study was to evaluate the current antibiotic susceptibility of H. pylori in an Icelandic cohort.
dc.description.abstractPatients referred for gastroscopy were recruited prospectively. Those found to have a positive rapid urease test were included in the study. Susceptibility testing was conducted by the Epsilometer test (E-test) method for ampicillin, clarithromycin, levofloxacin, metronidazole and tetracycline. Results were obtained after three days of incubation in microaerophilic conditions at 37 °C, except for the metronidazole were the first 24 hours were anaerobic.
dc.description.abstractOf the 613 patients who underwent gastroscopy, 138 (23%) had a positive rapid urease test. H. pylori was successfully cultured from 105 (76%) of the urease test positive patients and the isolates were tested for antibiotic susceptibility. Five patients had prior H. pylori eradication. Antibiotic resistance for ampicillin, clarithromycin, levofloxacin, metronidazole and tetracycline was 0%, 9%, 4%, 1% and 0%, respectively. If those who had previously undergone eradication treatment were excluded, the resistance was 0%, 6%, 3%, 1% and 0%, respectively. Clarithromycin resistance was higher amongst women than men, 13% vs. 5%, however, not significantly. Clarithromycin resistance was 60% amongst those who had previously received eradication treatment compared to 6% of those who had not (p < .0001).
dc.description.abstractClarithromycin resistance amongst the H. pylori isolates can be considered relatively low. Therefore, in the current cohort, standard triple-drug clarithromycin-containing regimen should remain the first-line treatment against H. pylori.
dc.description.sponsorshipActavis Group ptc Landspitali University Hospital of Icelanden
dc.language.isoenen
dc.publisherTaylor & Francisen
dc.relation.urlhttp://www.tandfonline.com/doi/pdf/10.1080/23744235.2017.1317359?needAccess=trueen
dc.rightsArchived with thanks to Infectious diseases (London, England)en
dc.subjectBakteríusjúkdómaren
dc.subjectLyfjameðferðen
dc.subjectMagasáren
dc.subjectGAS12en
dc.subjectLYF12en
dc.subjectBAC12en
dc.subject.meshHelicobacter pylorien
dc.subject.meshDrug Resistance, Bacterialen
dc.titleAntibiotic susceptibility of Helicobacter pylori in Iceland.en
dc.typeArticleen
dc.contributor.department[ 1 ] Natl Univ Hosp Iceland, Landspitali, Hosp Pharm, Reykjavik, Iceland Show the Organization-Enhanced name(s) [ 2 ] Univ Iceland, Fac Pharmaceut Sci, Reykjavik, Iceland Show the Organization-Enhanced name(s) [ 3 ] Natl Univ Hosp Iceland, Landspitali, Dept Internal Med, Reykjavik, Iceland Show the Organization-Enhanced name(s) [ 4 ] Univ Iceland, Fac Med, Reykjavik, Iceland Show the Organization-Enhanced name(s) [ 5 ] Natl Univ Hosp Iceland, Landspitali, Dept Clin Microbiol, Reykjavik, Icelanden
dc.identifier.journalInfectious diseases (London, England)en
dc.rights.accessLandspitali Access - LSH-aðganguren
html.description.abstractIncreasing resistance of Helicobacter pylori (H. pylori) to antibiotics calls for constant re-evaluation of multidrug regimens that have been used to eradicate the infection. The aim of this study was to evaluate the current antibiotic susceptibility of H. pylori in an Icelandic cohort.
html.description.abstractPatients referred for gastroscopy were recruited prospectively. Those found to have a positive rapid urease test were included in the study. Susceptibility testing was conducted by the Epsilometer test (E-test) method for ampicillin, clarithromycin, levofloxacin, metronidazole and tetracycline. Results were obtained after three days of incubation in microaerophilic conditions at 37 °C, except for the metronidazole were the first 24 hours were anaerobic.
html.description.abstractOf the 613 patients who underwent gastroscopy, 138 (23%) had a positive rapid urease test. H. pylori was successfully cultured from 105 (76%) of the urease test positive patients and the isolates were tested for antibiotic susceptibility. Five patients had prior H. pylori eradication. Antibiotic resistance for ampicillin, clarithromycin, levofloxacin, metronidazole and tetracycline was 0%, 9%, 4%, 1% and 0%, respectively. If those who had previously undergone eradication treatment were excluded, the resistance was 0%, 6%, 3%, 1% and 0%, respectively. Clarithromycin resistance was higher amongst women than men, 13% vs. 5%, however, not significantly. Clarithromycin resistance was 60% amongst those who had previously received eradication treatment compared to 6% of those who had not (p < .0001).
html.description.abstractClarithromycin resistance amongst the H. pylori isolates can be considered relatively low. Therefore, in the current cohort, standard triple-drug clarithromycin-containing regimen should remain the first-line treatment against H. pylori.


This item appears in the following Collection(s)

Show simple item record